Scientific Vita


Marco Binder

Academic Education and University Degree
2003 - 2007
Ph.D. thesis, Molecular Virology, Department of Infectious Diseases, Heidelberg University, Germany (highest grade: summa cum laude); supervised by Dr. Volker Lohmann / Prof. Ralf Bartenschlager
2001 - 2002
Diploma work, Biology, Stony Brook University (MCB program, Prof. Eckard Wimmer), New York, USA and University of Constance; Germany, supervised Prof. Patrick Hearing and Prof. Rolf Knippers (highest grade “sehr gut”)
1998 - 2003
Study of Biology at University of Constance, Germany

Since 2014
Independent group leader, division “Virus-associated carcinogenesis”, German Cancer Research Center Heidelberg, Germany
2011 - 2014
Research group leader, Dept. for Infectious Diseases, Heidelberg University, Germany
2009 - 2010
Postdoctoral Fellowship of the Medical Faculty Heidelberg, Germany associated with the Dept. for Infectious Diseases
2007 - 2008
Postdoc, Dept. Infectious Diseases, Heidelberg University, Germany
Cadena C, Ahmad S, Xavier A, Willemsen J, Park S, Park JW, Oh SW, Fujita T, Hou F, Binder M, Hur S. 2019. Ubiquitin-Dependent and -Independent Roles of E3 Ligase RIPLET in Innate Immunity. Cell. 177(5):1187-1200.e16.
Willemsen J, Wicht O, Wolanski JC, Baur N, Bastian S, Haas DA, Matula P, Knapp B, Meyniel-Schicklin L, Wang C, Bartenschlager R, Lohmann V, Rohr K, Erfle H, Kaderali L, Marcotrigiano J, Pichlmair A, Binder M. 2017. Phosphorylation-Dependent Feedback Inhibition of RIG-I by DAPK1 Identified by Kinome-wide siRNA Screening. Mol Cell. 65 (3):403–415.
Bender S, Reuter A, Eberle F, Einhorn E, Binder M, Bartenschlager R. 2015. Activation of Type I and III Interferon Response by Mitochondrial and Peroxisomal MAVS and Inhibition by Hepatitis C Virus. PLoS Pathogens. 11: e1005264.
Binder, M., Sulaimanov, N., Clausznitzer, D., Schulze, M., Hüber, C. M., Lenz, S. M., Schlöder, J. P., Trippler, M., Bartenschlager, R., Lohmann, V., Kaderali, L. 2013. Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle. PLoS Pathog. 9: e1003561.
Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M, Stefanovic A, Eberle CA, Goncalves A, Bürckstümmer T, Müller AC, Fauster A, Holze C, Lindsten K, Goodbourn S, Kochs G, Weber F, Bartenschlager R, Bowie AG, Bennett KL, Colinge J, Superti-Furga G. 2012. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature. 487(7408):486-90.
Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R. 2012. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology. 56(6): 2082–2093.
Binder M, Eberle F, Seitz S, Mücke N, Hüber CM, Kiani N, Kaderali L, Lohmann V, Dalpke A, Bartenschlager R. 2011. Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem. 286(31): 27278–27287.
Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, Lohmann V. 2007. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol. 81(10): 5270–5283.
Binder M, Kochs G, Bartenschlager R, Lohmann V. 2007. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology. 46(5): 1365–1374.
Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 437(7062): 1167–1172.
Division Virus-associated carcinogenesis (F170)
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg